

Lara N Roberts

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9034735/publications.pdf>

Version: 2024-02-01

75
papers

1,757
citations

377584

21
h-index

340414

39
g-index

76
all docs

76
docs citations

76
times ranked

2346
citing authors

#	ARTICLE	IF	CITATIONS
1	Rivaroxaban for the treatment of superficial vein thrombosis, experience at King's College Hospital. British Journal of Haematology, 2022, 196, .	1.2	3
2	Clinical outcomes and the impact of prior oral anticoagulant use in patients with coronavirus disease 2019 admitted to hospitals in the UK: a multicentre observational study. British Journal of Haematology, 2022, 196, 79-94.	1.2	8
3	Prevalence of Bleeding and Thrombosis in Critically Ill Patients with Chronic Liver Disease. Thrombosis and Haemostasis, 2022, 122, 1006-1016.	1.8	16
4	Periprocedural management of abnormal coagulation parameters and thrombocytopenia in patients with cirrhosis: Guidance from the SSC of the ISTH. Journal of Thrombosis and Haemostasis, 2022, 20, 39-47.	1.9	39
5	Evaluation of novel coagulation and platelet function assays in patients with chronic kidney disease. Journal of Thrombosis and Haemostasis, 2022, 20, 845-856.	1.9	14
6	Venous thromboembolism in patients hospitalised with COVID-19 in England. Thrombosis Research, 2022, 213, 138-144.	0.8	9
7	Illustrated State-of-the-Art Capsules of the ISTH 2022 Congress. Research and Practice in Thrombosis and Haemostasis, 2022, 6, e12747.	1.0	4
8	Prophylactic fresh frozen plasma and platelet transfusion have a prothrombotic effect in patients with liver disease. Journal of Thrombosis and Haemostasis, 2021, 19, 664-676.	1.9	29
9	Switching warfarin patients to a direct oral anticoagulant during the Coronavirus Disease-19 pandemic. Thrombosis Research, 2021, 197, 192-194.	0.8	11
10	Vascular Liver Disorders, Portal Vein Thrombosis, and Procedural Bleeding in Patients With Liver Disease: 2020 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology, 2021, 73, 366-413.	3.6	295
11	More on enoxaparin thromboprophylaxis in pregnancy: A review of 10 years' experience from King's College Hospital. Journal of Thrombosis and Haemostasis, 2021, 19, 304-308.	1.9	3
12	The effect of microgravity on the human venous system and blood coagulation: a systematic review. Experimental Physiology, 2021, 106, 1149-1158.	0.9	31
13	Fixed dose rivaroxaban can be used in extremes of bodyweight: A population pharmacokinetic analysis - Reply to Jacobs & Ryan comment. Journal of Thrombosis and Haemostasis, 2021, 19, 872-873.	1.9	0
14	The concept of rebalanced hemostasis in patients with liver disease: Communication from the ISTH SSC working group on hemostatic management of patients with liver disease. Journal of Thrombosis and Haemostasis, 2021, 19, 1116-1122.	1.9	66
15	Heparins have adequate ex vivo anticoagulant effects in hospitalized patients with cirrhosis. Journal of Thrombosis and Haemostasis, 2021, 19, 1472-1482.	1.9	3
16	Three-month follow-up of pulmonary embolism in patients with COVID-19. Thrombosis Research, 2021, 201, 113-115.	0.8	18
17	Treatment of bleeding in patients with liver disease. Journal of Thrombosis and Haemostasis, 2021, 19, 1644-1652.	1.9	16
18	Rivaroxaban in acute venous thromboembolism: UK prescribing experience. Research and Practice in Thrombosis and Haemostasis, 2021, 5, e12607.	1.0	4

#	ARTICLE	IF	CITATIONS
19	Adherence to rivaroxaban for the treatment of venous thromboembolism—Results from the FIRST registry. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2021, 5, e12614.	1.0	3
20	Long-term adherence to direct acting oral anticoagulants and the influence of health beliefs after switching from vitamin-K antagonists: Findings from the Switching Study. <i>Thrombosis Research</i> , 2021, 208, 162-169.	0.8	5
21	Rebalanced hemostasis in liver disease: a misunderstood coagulopathy. <i>Hematology American Society of Hematology Education Program</i> , 2021, 2021, 485-491.	0.9	6
22	Mode of Delivery Does Not Influence Postpartum Hypercoagulability Measured by Thrombin Generation or Thromboelastometry. <i>TH Open</i> , 2020, 04, e1-e11.	0.7	2
23	Pulmonary embolism mortality trends in the European region—too good to be true?. <i>Lancet Respiratory Medicine</i> , 2020, 8, e2.	5.2	3
24	Incidence of Bleeding and Thrombosis in Patients with Liver Disease. <i>Seminars in Thrombosis and Hemostasis</i> , 2020, 46, 656-664.	1.5	15
25	Automated Inferior Vena Cava Filter Retrieval Requests and Hematology Liaison Improves Retrieval and Reduces the Use of Temporary Inferior Vena Cava Filters. <i>TH Open</i> , 2020, 04, e116-e118.	0.7	1
26	Postdischarge venous thromboembolism following hospital admission with COVID-19. <i>Blood</i> , 2020, 136, 1347-1350.	0.6	164
27	Hypercoagulability and Anticoagulation in Patients With COVID-19 Requiring Renal Replacement Therapy. <i>Kidney International Reports</i> , 2020, 5, 1377-1380.	0.4	7
28	Tranexamic acid in acute gastrointestinal bleeding — A cautionary tale. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 2440-2443.	1.9	3
29	Fixed dose rivaroxaban can be used in extremes of bodyweight: A population pharmacokinetic analysis. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 2296-2307.	1.9	37
30	Comment on Comparison of three transfusion protocols prior to central venous catheterisation in patients with cirrhosis; a randomised controlled trial. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 753-754.	1.9	1
31	Pulmonary embolism in hospitalised patients with COVID-19. <i>Thrombosis Research</i> , 2020, 195, 95-99.	0.8	75
32	Whole blood thrombin generation profiles of patients with cirrhosis explored with a near patient assay. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 834-843.	1.9	22
33	Thromboprophylaxis in temporary lower limb immobilization: Extrapolate with care. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 518-519.	1.9	0
34	Direct oral anticoagulants for the management of venous thromboembolism in patients with HIV — a single centre experience. <i>British Journal of Haematology</i> , 2019, 186, e148-e151.	1.2	5
35	What are the difficulties in conducting randomised controlled trials of thromboprophylaxis in myeloma patients and how can we address these? Lessons from apixaban versus LMWH or aspirin as thromboprophylaxis in newly diagnosed multiple myeloma (TiMM) feasibility clinical trial. <i>Journal of Thrombosis and Thrombolysis</i> , 2019, 48, 315-322.	1.0	8
36	Venous thromboembolism. <i>Clinical Medicine</i> , 2019, 19, 262.1-262.	0.8	3

#	ARTICLE	IF	CITATIONS
37	Women's views, adherence and experience with postnatal thromboprophylaxis. <i>Thrombosis Research</i> , 2019, 173, 85-90.	0.8	12
38	Prothrombin times in the presence of edoxaban <i>in vivo</i> experience from King's College hospital. <i>British Journal of Haematology</i> , 2019, 184, 455-456.	1.2	2
39	Exploration of adherence and patient experiences with DOACs one year after switching from vitamin-K antagonists- insights from the switching study. <i>Thrombosis Research</i> , 2018, 162, 62-68.	0.8	19
40	Single centre experience of the management of superficial vein thrombosis with prophylactic low molecular weight heparin. <i>British Journal of Haematology</i> , 2018, 181, 682-684.	1.2	3
41	Re: Pregnancy outcomes in women with mechanical prosthetic heart valves – a prospective descriptive population-based study using the United Kingdom Obstetric Surveillance System (UKOSS) data collection system. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2018, 125, 96-96.	1.1	4
42	Venous thromboembolism and women's health. <i>British Journal of Haematology</i> , 2018, 183, 346-363.	1.2	24
43	Sub therapeutic rivaroxaban plasma concentrations following administration via Percutaneous Endoscopic Gastrostomy (PEG) feeding tubes – A note of caution. <i>Thrombosis Research</i> , 2018, 168, 102-103.	0.8	3
44	Associations between illness beliefs, medication beliefs, anticoagulation-related quality of life, and INR control: Insights from the Switching Study. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2018, 2, 497-507.	1.0	17
45	Annotation: Developing a national programme for VTE prevention. <i>British Journal of Haematology</i> , 2017, 178, 162-170.	1.2	24
46	Re: A comparison of the recommendations for pharmacologic thromboembolism prophylaxis after caesarean delivery from the major guidelines. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2017, 124, 831-832.	1.1	6
47	The impact of body weight on rivaroxaban pharmacokinetics. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2017, 1, 180-187.	1.0	44
48	Thrombin Generation in Acute Ischaemic Stroke. <i>Stroke Research and Treatment</i> , 2016, 2016, 1-9.	0.5	8
49	Clinical and laboratory predictors of deep vein thrombosis after acute stroke. <i>Thrombosis Research</i> , 2016, 142, 33-39.	0.8	30
50	Heavy menstrual bleeding on rivaroxaban. <i>British Journal of Haematology</i> , 2016, 173, 314-315.	1.2	53
51	Clinical and laboratory predictors of deep vein thrombosis after acute stroke: Does D-dimer really improve predictive power?. <i>Thrombosis Research</i> , 2016, 146, 133-134.	0.8	1
52	Anticoagulated patient's perception of their illness, their beliefs about the anticoagulant therapy prescribed and the relationship with adherence: impact of novel oral anticoagulant therapy – study protocol for The Switching Study: a prospective cohort study. <i>BMC Hematology</i> , 2016, 16, 22.	2.6	5
53	Relationship between development of post-thrombotic syndrome and serial ultrasound, D-dimer, and factor VIII activity after a first deep venous thrombosis. <i>Journal of Vascular Surgery: Venous and Lymphatic Disorders</i> , 2016, 4, 28-35.	0.9	13
54	Changing paradigms in the management of deep vein thrombosis. <i>British Journal of Haematology</i> , 2015, 170, 162-174.	1.2	6

#	ARTICLE	IF	CITATIONS
55	Normal prothrombin times in the presence of therapeutic levels of apixaban "in vivo" experience from King's College Hospital. <i>British Journal of Haematology</i> , 2015, 169, 152-153.	1.2	12
56	Management of Bleeding and Thrombosis in Critically Ill Patients with Liver Disease. <i>Seminars in Thrombosis and Hemostasis</i> , 2015, 41, 520-526.	1.5	20
57	The First Registry: Follow-up in Rivaroxaban Patients in the Setting of Venous Thromboembolism. <i>Blood</i> , 2015, 126, 4737-4737.	0.6	1
58	Changes in thrombin generation and D-dimer concentrations in women injecting enoxaparin during pregnancy and the puerperium. <i>BMC Pregnancy and Childbirth</i> , 2014, 14, 384.	0.9	16
59	Evidence of rebalanced coagulation in acute liver injury and acute liver failure as measured by thrombin generation. <i>Liver International</i> , 2014, 34, 672-678.	1.9	77
60	Women with unexplained recurrent pregnancy loss do not have evidence of an underlying prothrombotic state: Experience with calibrated automated thrombography and rotational thromboelastometry. <i>Thrombosis Research</i> , 2014, 133, 892-899.	0.8	11
61	Post-thrombotic syndrome is an independent determinant of health-related quality of life following both first proximal and distal deep vein thrombosis. <i>Haematologica</i> , 2014, 99, e41-e43.	1.7	33
62	More on normal prothrombin times in the presence of therapeutic levels of rivaroxaban "early experience from King's College Hospital. <i>British Journal of Haematology</i> , 2013, 162, 717-718.	1.2	12
63	Presenting D-dimer and early symptom severity are independent predictors for post-thrombotic syndrome following a first deep vein thrombosis. <i>British Journal of Haematology</i> , 2013, 160, 817-824.	1.2	28
64	African/Caribbean ethnicity is associated with a hypercoagulable state as measured by thrombin generation. <i>Blood Coagulation and Fibrinolysis</i> , 2013, 24, 40-49.	0.5	31
65	Comprehensive VTE Prevention Program Incorporating Mandatory Risk Assessment Reduces the Incidence of Hospital-Associated Thrombosis. <i>Chest</i> , 2013, 144, 1276-1281.	0.4	47
66	Anticoagulating obese patients in the modern era. <i>British Journal of Haematology</i> , 2011, 155, 137-149.	1.2	86
67	Deep vein thrombosis and pulmonary embolism: diagnosis, treatment and prevention. <i>Clinical Medicine</i> , 2011, 11, 465-466.	0.8	5
68	Outcomes From Root Cause Analysis of Hospital-Associated Thrombosis Over Twelve Months: A Single Centre Experience. <i>Blood</i> , 2011, 118, 675-675.	0.6	5
69	Haemostasis and thrombosis in liver disease. <i>British Journal of Haematology</i> , 2010, 148, 507-521.	1.2	85
70	New Anticoagulants for Prevention and Treatment of Venous Thromboembolism. <i>Current Vascular Pharmacology</i> , 2010, 8, 373-382.	0.8	2
71	Mean Platelet Volume as a Risk Factor for Deep Vein Thrombosis In An Ethnically Diverse Population. <i>Blood</i> , 2010, 116, 4211-4211.	0.6	0
72	Identifying Patients at High Risk for Deep Vein Thrombosis (DVT) After Acute Stroke Using Clinical and Laboratory Predictors. <i>Blood</i> , 2010, 116, 3825-3825.	0.6	0

#	ARTICLE	IF	CITATIONS
73	Stroke prevention in the young child with sickle cell anaemia. <i>Annals of Hematology</i> , 2009, 88, 943-946.	0.8	5
74	Venous thromboembolism and ethnicity. <i>British Journal of Haematology</i> , 2009, 146, 369-383.	1.2	78
75	Leukaemic Monocytoid Marginal Zone Lymphoma (LMMZL): A Rare Undescribed Lymphoproliferative Disorder with Unique Features.. <i>Blood</i> , 2007, 110, 4424-4424.	0.6	0